BioHarvest Sciences Inc. Closes First Tranche of Private Placement

- September 14th, 2020

BioHarvest Sciences Inc. announced today that it has closed the first tranche of its private placement financing disclosed in its news release dated September 8th, 2020. The first tranche consisted of 21,492,221 common shares at a price of $0.15 per share for aggregate gross proceeds of $3,223,833.15, net proceeds of $3,107,984.20 after payment of finder’s fees totalling $115,848.95.The private placement is part of …

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company”, “BioHarvest”) announced today that it has closed the first tranche of its private placement financing (the “Private Placement Financing”) disclosed in its news release dated September 8th, 2020. The first tranche consisted of 21,492,221 common shares at a price of $0.15 per share for aggregate gross proceeds of $3,223,833.15, net proceeds of $3,107,984.20 after payment of finder’s fees totalling $115,848.95.

The private placement is part of a total private placement of up to 25,428,055 common shares at a price of $0.15 per share. In connection to the first tranche closing, the Company also issued 680,545 finder’s warrants. The finder’s warrants are exercisable to purchase a common share of the Company at a price of $0.15 per share for a period of 1 year from the date of issuance.

The securities issued under the private placement will have a hold period expiring four months and one day from the date of issuance pursuant to applicable Canadian securities laws.

The funds will be used to invest in the required Capital Equipment for BioHarvest’s planned 20 Ton BioFarming manufacturing facility, and for general corporate purposes.

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent protected Biofarming technology. It is the first and only industrial large-scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself. The technology has been already validated by Vinia®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest. By adapting this technology to the Cannabis plant, and building adequate cells production capacity, BioHarvest Sciences Inc.‘s objective is to become the leading supplier of Cannabis for both the medicinal and recreational legal use. See the following hyperlink for a visual description of our Biofarming technology: BHSC’s Biofarming Technology

BioHarvest Sciences Inc.
Dr. Zaki Rakib
President and Chairman of the Board

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are no guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/63766

copyright (c) newsfile corp. 2020

News Provided by Newsfile via QuoteMedia

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply